You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Kevin Caliendo
since
auto-detected in 1 stories
7 months ago
UBS analyst Kevin Caliendo's revised price target implies 15% upside ahead for shares of the health care benefit and pharmacy chain.
page 1 of 1